Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5642631 | Oral Oncology | 2017 | 4 Pages |
Abstract
Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Quynh Thu Le, John J. Welch, Jan B. Vermorken, Danny Rischin, Hisham Mehanna, on behalf of all HNCIG investigators on behalf of all HNCIG investigators,